We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| MGC Pharmaceuticals Ltd | ASX:MXC | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.395 | 0.395 | 0.42 | 0.00 | 01:00:00 |
From May 2023 to May 2024
By Joe Hoppe
MGC Pharmaceuticals said results from a preclinical toxicology trial of its anti-inflammatory drug Cimetra were positive, finding the drug to be safe.
The London and Australia-listed biopharma company said Monday that the study, a full chronic safety and toxicology analysis of the drug in large animals, demonstrated all tissues of all animals were normal and unaffected.
The study was for a 14-day oral dose of Cimetra, undertaken on 32 domestic swine.
The study is an important step in the Investigational New Drug application preparation for the U.S. Food and Drug Administration, with submission planned for the first quarter of 2024, the company said.
"The potential addressable market for our anti-inflammatory and immunomodulating product is considerable and this represents a key milestone for the business," Chief Executive and Managing Director Roby Zomer said.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
August 14, 2023 02:48 ET (06:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year MGC Pharmaceuticals Chart |
1 Month MGC Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
